Comparison 1. Botulinum toxin type A (BtA) versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Blepharospasm‐specific severity	3		Mean Difference (IV, Random, 95% CI)	0.93 [0.61, 1.25]
1.2 Blepharospasm‐specific disability	3	290	Mean Difference (IV, Random, 95% CI)	0.69 [0.18, 1.19]
1.3 Adverse events	2	169	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [0.87, 1.60]
1.4 Vision complaints (diplopia, blurred vision, visual disturbance)	2	228	Risk Ratio (M‐H, Fixed, 95% CI)	5.73 [1.79, 18.36]
1.5 Eyelid ptosis	3	289	Risk Ratio (M‐H, Fixed, 95% CI)	4.02 [1.61, 10.00]
1.6 Increased lacrimation	2	228	Risk Ratio (M‐H, Fixed, 95% CI)	2.04 [0.46, 9.13]
1.7 Xerophthalmia	2	228	Risk Ratio (M‐H, Fixed, 95% CI)	1.83 [0.69, 4.86]
1.8 Frequency of blepharospasm‐specific involuntary movements	2		Std. Mean Difference (IV, Random, 95% CI)	0.79 [0.31, 1.27]
1.9 Subjective participant evaluation	2	170	Std. Mean Difference (IV, Fixed, 95% CI)	0.86 [0.53, 1.20]
1.10 Tolerability – dropouts	2	169	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [0.31, 6.79]